Home › Kanser sa Dugo › Texas › Houston
Pag-aaral pangklinika para sa Kanser sa Dugo sa Houston, TX
46 pag-aaral para sa Kanser sa Dugo ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Houston (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Nagre-recruitPhase 1
- UT MD Anderson Cancer Center, Houston
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Nagre-recruitPhase 3
- University of Texas MD Anderson Cancer Center ( Site 0007), Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- UT MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Nagre-recruitObservasyonal na pag-aaral
- Texas Children's Hospital, Houston
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Nagre-recruitPhase 1
- MD Anderson Cancer Center - University of Texas, Houston
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Nagre-recruitPhase 3
- Quetzal Site 6, Houston
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Nagre-recruitMaagang Phase 1
- M D Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Nagre-recruitPhase 3
- The University of Texas MD Anderson Cancer Center, Houston
Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions
Nagre-recruitObservasyonal na pag-aaral
- UT MD Anderson Cancer Center, Houston
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Nagre-recruitPhase 1
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Nagre-recruitPhase 1
- Md Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Nagre-recruitPhase 2
- The University of Texas MD Anderson Cancer Center, Houston
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
Nagre-recruit
- M D Anderson Cancer Center, Houston
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
- M D Anderson Cancer Center, Houston
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Nagre-recruitPhase 1
- M D Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Nagre-recruitPhase 1/2
- MD Anderson, Houston
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
Nagre-recruitObservasyonal na pag-aaral
- M D Anderson Cancer Center, Houston
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Nagre-recruitPhase 3
- University of Texas, Houston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Nagre-recruitPhase 1/2
- M D Anderson Cancer Center, Houston
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
Nagre-recruitMaagang Phase 1
- M D Anderson Cancer Center, Houston
Expressive Writing for the Management of Stress in Cancer Survivors
Nagre-recruit
- M D Anderson Cancer Center, Houston
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
Nagre-recruitObservasyonal na pag-aaral
- M D Anderson Cancer Center, Houston
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
The Impact of COVID-19 on Pulmonary Procedures
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- M D Anderson Cancer Center, Houston
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Nagre-recruitPhase 2
- University of Texas MD Anderson MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Nagre-recruitPhase 1
- The University of TX MD Anderson Cancer Center, Houston
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
Nagre-recruitPhase 2
- M D Anderson Cancer Center, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Nagre-recruitObservasyonal na pag-aaral
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
Improving Comprehensive Care of Cancer Patients
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Baylor College of Medicine, Houston
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Nagre-recruitObservasyonal na pag-aaral
- M D Anderson Cancer Center, Houston
The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors
Nagre-recruitObservasyonal na pag-aaral
- M D Anderson Cancer Center, Houston
Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- M D Anderson Cancer Center, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Nagre-recruitObservasyonal na pag-aaral
- M D Anderson Cancer Center, Houston
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Nagre-recruitPhase 2
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Nagre-recruitPhase 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
Nagre-recruit
- M D Anderson Cancer Center, Houston
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
Nagre-recruitPhase 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies
Nagre-recruitObservasyonal na pag-aaral
- M D Anderson Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Nagre-recruitPhase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Nagre-recruitPhase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Nagre-recruitPhase 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
Pag-aaral para sa Kanser sa Dugo sa ibang lungsod
- New York City, NY26 pag-aaral
- Boston, MA25 pag-aaral
- Washington, DC19 pag-aaral
- Seattle, WA18 pag-aaral
- Baltimore, MD18 pag-aaral
- Los Angeles, CA17 pag-aaral
- Durham, NC16 pag-aaral
- Chicago, IL15 pag-aaral
- Philadelphia, PA14 pag-aaral
- Nashville, TN13 pag-aaral
- Edison, NJ13 pag-aaral
- Columbus, OH13 pag-aaral
Iba pang pag-aaral sa Houston
- Non-Small Cell Lung Cancer145 pag-aaral
- Kanser sa Suso126 pag-aaral
- Kanser (lahat ng uri)121 pag-aaral
- Metastatic Cancer104 pag-aaral
- Colorectal Cancer102 pag-aaral
- Kanser sa Ovary89 pag-aaral
- Acute Myeloid Leukemia85 pag-aaral
- Kanser sa Baga78 pag-aaral
- Kanser sa Prostate76 pag-aaral
- Kanser ng Endometrium68 pag-aaral
- Kanser sa Pancreas61 pag-aaral
- Melanoma59 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.